RESULTS	The impact of statin use did not differ by tumor KRAS mutation status , with similar DFS , RFS , and OS for statin use among mutant and wild-type subgroups ( P ( interaction ) = .84 , .67 , and .98 for DFS , RFS , and OS , respectively ) .\